- Contract Awards
Emergent BioSolutions (NYSE: EBS) has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to deliver BioThrax anthrax vaccines to the Strategic National Stockpile. The award came three months after the Centers for Disease Control and Prevention awarded Emergent a potenti...